CXCL9 and primary cutaneous T-cell non-Hodgkin lymphoma: In treated CTCL skin lesions, CXCL9 and CXCL11 are markedly upregulated, primarily secreted by infiltrating macrophages, which promote the accumulation of CXCR3+ effector T cells within the skin and establish a distinct TME [18].